Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Array BioPharma
Sponsor:
Information provided by (Responsible Party):
Array BioPharma
ClinicalTrials.gov Identifier:
NCT01781572
First received: January 24, 2013
Last updated: September 30, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)